Purvesh Kumar Khatri

US Patent:

20130143755, Jun 6, 2013

Filed:

Mar 25, 2011

Appl. No.:

13/635667

Inventors:

Minnie M. Sarwal - Portola Valley CA, US
Tara Sigdel - Palo Alto CA, US
Amit Kaushal - Los Altos CA, US
Li Li - Fremont CA, US
Wenzhong Xiao - San Jose CA, US
Atul J. Butte - Menlo Park CA, US
Purvesh Khatri - Stanford CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

G01N 33/68
C12Q 1/68

US Classification:

506 9, 506 12

Abstract:

Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding AR mechanism (graft biopsy), as well as monitoring by minimal invasive means (blood) or non-invasive means (urine for the kidney allograft). For biomarker discovery different categories of markers are examined such as genes, proteins, peptides and antibodies. These biomarkers can help determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK viremia, BK nephritis, drug toxicity or chronic allograft injury (CAI), and the like). Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.

US Patent:

20200303078, Sep 24, 2020

Filed:

Mar 20, 2020

Appl. No.:

16/826042

Inventors:

- Burlingame CA, US
Ljubomir Buturovic - Burlingame CA, US
Timothy E. Sweeney - Burlingame CA, US
Roland Luethy - Burlingame CA, US
Purvesh Khatri - Burlingame CA, US

Assignee:

Inflammatix, Inc. - Burlingame CA

International Classification:

G16H 50/30
G16B 20/00
G16B 40/00
G06N 7/00
G06N 3/08
G06N 20/10
G06N 20/20

Abstract:

Systems and methods for subject clinical condition evaluation using a plurality of modules are provided. Modules comprise features whose corresponding feature values associate with an absence, presence or stage of phenotypes associated with the clinical condition. A first dataset is obtained having feature values, acquired through a first technical background from respective subjects in transcriptomic, proteomic, or metabolomic form, for at least a first of the plurality of modules. A second training dataset is obtained having feature values, acquired through a technical background other than the first technical background, from training subjects of the second dataset, in the same form as for the first dataset, of at least the first module. Inter-dataset batch effects are removed by co-normalizing feature values across the training datasets, thereby calculating co-normalized feature values used to train a classifier for clinical condition evaluation of the test subject.

US Patent:

20200206214, Jul 2, 2020

Filed:

May 18, 2018

Appl. No.:

16/614778

Inventors:

- Palo Alto CA, US
Svenja DANNEWITZ PROSSEDA - Graevenwiesbach, DE
Xuefei TIAN - Fremont CA, US
Purvesh KHATRI - Stanford CA, US

International Classification:

A61K 31/4545
A61K 45/06
A61P 11/00
A61P 9/12

Abstract:

The present invention provides methods for treatment or prevention of pulmonary hypertension and emphysema using agents that increase activity of FHIT, such as Enzastaurin. Included are methods for using levels of FHIT and/or BMPR2, and checking for mutations in FHIT and/or BMPR2, to select patients for treatment or to monitor effectiveness of treatment. The invention is based on evidence that Enzastaurin prevents and reverses pulmonary hypertension induced in animal model systems, and that it acts by up-regulation of FHIT and/or BMPR2.

US Patent:

20190094223, Mar 28, 2019

Filed:

Apr 6, 2017

Appl. No.:

16/091988

Inventors:

- Haifa, IL
- Stanford CA, US
Naama MAIMON - Nir-Etzion, IL
Purvesh KHATRI - Menlo Park CA, US
Renaud GAUJOUX - Cape Town, ZA
Francesco VALLANIA - San Fransisco CA, US

Assignee:

Technion Research & Development Foundation Limited - Haifa
The Board of Trustees of the Leland Stanford Junior University - Stanford CA

International Classification:

G01N 33/569
C12Q 1/6883

Abstract:

Provided are methods of predicting responsiveness of a subject having an inflammatory bowel disease (IBD) to a tumor necrosis factor (TNF)-alpha inhibitor, by analyzing a frequency of at least one subpopulation of immune cells in a tissue biopsy of the subject. Also provided are methods of selecting a treatment for a subject and kits for determining responsiveness of the subject to treatment with a TNF-alpha inhibitor.

US Patent:

20170227549, Aug 10, 2017

Filed:

Nov 22, 2016

Appl. No.:

15/359308

Inventors:

- Stanford CA, US
Tara Sigdel - Palo Alto CA, US
Amit Kaushal - Mountain View CA, US
Li Li - Stanford CA, US
Wenzhong Xiao - San Jose CA, US
Atul J. Butte - Menlo Park CA, US
Purvesh Khatri - Menlo Park CA, US

International Classification:

G01N 33/68
C12Q 1/68

Abstract:

Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding AR mechanism (graft biopsy), as well as monitoring by minimal invasive means (blood) or non-invasive means (urine for the kidney allograft). For biomarker discovery different categories of markers are examined such as genes, proteins, peptides and antibodies. These biomarkers can help determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK viremia, BK nephritis, drug toxicity or chronic allograft injury (CAI), and the like). Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.

US Patent:

20170121774, May 4, 2017

Filed:

Oct 27, 2016

Appl. No.:

15/336590

Inventors:

- Stanford CA, US
Purvesh Khatri - Menlo Park CA, US

International Classification:

C12Q 1/68
G01N 33/68

Abstract:

Methods, systems (e.g., computer systems), compositions, and kits are provided for predicting whether an individual will respond to treatment with a TNF inhibitor, for determining a treatment regimen for an individual (e.g. a therapy that does or does not include administration of a TNF inhibitor), and for treating an individual. The subject methods include measuring an expression level of an RGS1 expression product and/or an expression level of an IL11 expression product in a biological sample from an individual. In some cases, the methods include a step of calculating a TNF inhibitor signature score from measured expression levels (e.g., calculating a geometric mean of the expression levels of an RGS1 expression product and an IL11 expression product). After comparing measured expression levels and/or a calculated TNF inhibitor signature score with a reference, one can predict whether an individual will respond to treatment with a TNF inhibitor.

US Patent:

20160291024, Oct 6, 2016

Filed:

Sep 17, 2014

Appl. No.:

14/914245

Inventors:

- Stanford CA, US
Linda Anne Szabo - Belmont CA, US
Purvesh Khatri - Menlo Park CA, US
Bruce Xuefeng Ling - Palo Alto CA, US

Assignee:

THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY - Stanford CA

International Classification:

G01N 33/574

Abstract:

Biomarkers and biomarker panels are provided for making ovarian cancer assessments, for example, diagnosing an ovarian cancer, predicting responsiveness of an ovarian cancer to an ovarian cancer therapy, and monitoring an ovarian cancer. A patient may further be treated in accordance with the classification. Also provided are methods, reagents, devices and kits for the use of these biomarkers in making ovarian cancer assessments.